pana veyxal ointment
veyx-pharma gmbh - Химотрипсин, трипсинът, папаин, ретинол пальмитат, α-токоферил ацетат - маз за кожа - 510 fip-u/10 g; 258 fip-u/10 g; 27,75 fip-u/10 g; 42 500 iu/10 g; 25.00 mg/10 g - говеда, кози, коне, кучета, овце, свине
oculotect gel 10,0 mg / g eye gel
laboratoires thea - Ретинол - 10,0 mg / g eye gel
vitamin a sopharma 40 000 iu/ml oral drops, solution
СОФАРМА АД - Ретинол - 40 000 iu/ml oral drops, solution
х 10ml
Софарма АД - Эргокальциферол, Ретинол -
vita-merfen 1 mg/g + 5 mg/g + 2000 iu/g ointment
novartis consumer health gmbh - Хлорхексидин, ретинол, хлорид benzoxonium - 1 mg/g + 5 mg/g + 2000 iu/g ointment
masti veyxym
veyx-pharma gmbh - α-tokoferol ацетат; ретинол пальмитат; химотрипсин; трипсинът; папаин - интрамамарна суспензия - 120.00 mg/10 g; corresponds to 100.000 iu/10 g; 2 400 fip-e/10 g; 240 fip-e/10 g; 6 fip-e/10 g - крави
masticlox m intramammary solution
Биовет АД - Мента; витамин А-пропионат ; витамин e ацетат - интрамамарен разтвор - 200 mg/10 g; 50 000 iu/10 g; 75 mg/10 g - крави
arsenic trioxide medac
medac gesellschaft für klinische spezialpräparate mbh - Арсеник Триоксид - Левкемия, промиелоцитна, остра - Антинеопластични средства - arsenic trioxide medac is indicated for induction of remission, and consolidation in adult patients with:newly diagnosed low-to-intermediate risk acute promyelocytic leukaemia (apl) (white blood cell count, ≤ 10 x 10³/μl) in combination with all-trans-retinoic acid (atra)relapsed/refractory apl (previous treatment should have included a retinoid and chemotherapy) characterised by the presence of the t(15;17) translocation and/or the presence of the pro-myelocytic leukaemia/retinoic-acid-receptor-alpha (pml/rarα) gene. Скоростта на реакция друг остър миелобластный подтипове на левкемия до триоксида арсен не е считан за.
ranivisio
midas pharma gmbh - ранимизумаб - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - Офталмологични - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).
yesafili
viatris limited - aflibercept - macular edema; retinal vein occlusion; diabetic retinopathy; myopia, degenerative; diabetes complications - Офталмологични - yesafili is indicated for adults for the treatment ofneovascular (wet) age-related macular degeneration (amd) (see section 5. 1),visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo) (see section 5. 1),visual impairment due to diabetic macular oedema (dme) (see section 5. 1),visual impairment due to myopic choroidal neovascularisation (myopic cnv) (see section 5.